Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02297386 · ClinicalTrials.gov registry record · Phase 1
[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02297386: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02297386 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02297386, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for \[18F\] Dihydro-Testosterone), to better find and monitor prostate cancer. Radiotracers are a type of drug that carries small amounts of radioactivity that can be seen by the PET scanner. FDHT is a radiotracer that looks for a protein which is present in almost all prostate cancer cells. The investigators want to find out if we can find and monitor changes in cancer using a FDHT PET scan.
Interventions
- OTHER Blood draw
- DEVICE MRI
- DEVICE PET scan
- DRUG [18F] DIHYDRO-TESTOSTERONE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02297386
The ClinicalTrials.gov registry entry for NCT02297386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Blood draw is the first listed.
NCT02297386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02297386 about?
NCT02297386 is a clinical study titled "[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer". The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for \[18F\] Dihydro-Testosterone), to better find and monitor prostate cancer. Radiotracers are a type of drug that carries small amounts of radioactivity that can be seen by the PET scanner. FDHT is ...
What is the current status of trial NCT02297386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02297386?
The interventions under investigation include: Blood draw (OTHER), MRI (DEVICE), PET scan (DEVICE), [18F] DIHYDRO-TESTOSTERONE (DRUG).
Who is sponsoring clinical trial NCT02297386?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.